Leukemia

San Diego, CA—A 2-year duration of combination immunotherapy with ven­etoclax (Venclexta) and rituximab (Ri­tuxan) improved survival compared with standard-of-care chemoimmunotherapy combination with bendamustine (Ben­deka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to follow-up data from the MURANO clinical trial presented at ASH 2018. Early results were first presented at ASH 2017.
San Diego, CA—The BCL2 Gly101Val mutation is the first genomic alteration to be identified as responsible for resistance to venetoclax (Venclexta), a potent and effective medication indicated for the treatment of chronic lymphocytic leukemia (CLL). The BCL2 Gly101Val mutation is unique to CLL and so far has not been described in other cancers.
San Diego, CA—More than 40% of older patients with acute myeloid leukemia (AML) associated with an IDH2 mutation achieved complete remission when treated with the IDH2 inhibitor enasidenib (Idhifa), according to results of a mutation-driven clinical trial substudy presented at ASH 2018.
San Diego, CA—Front-line ibrutinib (Imbruvica) therapy results in a lower rate of disease progression or death than the current standard-of-care chemoimmunotherapy with bendamustine (Ben­deka) and rituximab (Rituxan) in older patients with chronic lymphocytic leukemia (CLL). Adding rituximab to ibrutinib did not improve outcomes compared with ibrutinib alone, reported Jennifer A. Woyach, MD, Associate Professor, Ohio State University Comprehensive Cancer Center, Columbus, at ASH 2018.
Moving nelarabine (Arranon), a T-cell–specific drug, up front combined with backbone chemotherapy (ie, COG-augmented Berlin-Frankfurt-Münster [aBFM]) improved survival by approximately 10% in the largest-­ever randomized clinical trial enrolling newly diagnosed children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL).
Next-generation sequencing (NGS) and novel targeted agents have transformed cancer care for several solid tumors and hematologic malignancies, but when it comes to acute myeloid leukemia (AML), results of a recent study suggest that these tools may be considerably underutilized.
  • Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
  • Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Drugs with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
  • Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL
  • Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
  • Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: The GENUINE Study
  • COSMOS: MOR208 plus Idelalisib or Venetoclax in Relapsed/Refractory CLL or SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor
Chicago, IL—Survival with the use of a tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML) in the chronic phase is comparable among the available drugs, so other variables should come into play when selecting a specific TKI. In some instances, a treatment-free remission is possible, said CML experts at the 2017 ASCO annual meeting.
  • Allogeneic Transplant Leads to Markedly Improved Survival in Older Patients with AML
  • Effect of Cytarabine/Anthracycline/Crenolanib Induction on MRD in Newly Diagnosed AML with FLT3 Mutation
  • Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
  • Improved Survival with Fludarabine and Timed Sequential Busulfan Regimen in Older Patients with AML or MDS
  • Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with AML
  • Nivolumab with Azacytidine in Patients with Relapsed AML
San Diego, CA—Combination induction therapy with ibrutinib (Imbruvica) and rituximab (Rituxan) in patients with mantle-cell lymphoma (MCL) led to objective responses in each of the first 50 patients who received this combination in an ongoing, phase 2 clinical trial presented at the 2016 American Society of Hematology meeting.
Page 1 of 6
Results 1 - 10 of 52
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME